Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered ...

Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Innoviva (INVA) announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica for the commercialization of Zevtera, an advanced-generation cephalosporin ...

Cefixime is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines ...

Innoviva, Inc. (INVA) announced Monday that its unit Innoviva Specialty Therapeutics, Inc. or IST has entered into an exclusive ...

Research shows the presence of cloudy effluent in peritoneal dialysis-associated peritonitis is highly predictive of ...

Many authors have suggested using a cephalosporin as an alternative to penicillin. Casey and Pichichero performed a meta-analysis of 35 randomized, controlled trials comparing penicillin with ...

Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 16, 2024Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a ...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin ...

Typhoid fever might be rare in developed countries, but this ancient threat, thought to have been around for millennia, is ...